FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro) Meeting Abstract
| Authors: | Rosen, L. S.; Camidge, D. R.; Khalil, D.; Lillie, T.; Carter, J.; Krige, D.; Davies, J.; Miles, D.; Patel, M.; Evilevitch, V.; González-Albo, I. P.; Champion, B.; Naing, A. |
| Abstract Title: | FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300782 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.2559 |
| Notes: | Meeting Abstract: 2559 -- Meeting also held virtually -- Source: Wos |
